Shanghai Haohai Biological Technology Co., Ltd.

SEHK:6826 Stock Report

Market Cap: HK$15.0b

Shanghai Haohai Biological Technology Balance Sheet Health

Financial Health criteria checks 5/6

Shanghai Haohai Biological Technology has a total shareholder equity of CN¥6.1B and total debt of CN¥390.2M, which brings its debt-to-equity ratio to 6.4%. Its total assets and total liabilities are CN¥7.2B and CN¥1.1B respectively. Shanghai Haohai Biological Technology's EBIT is CN¥402.4M making its interest coverage ratio -5.7. It has cash and short-term investments of CN¥2.7B.

Key information

6.4%

Debt to equity ratio

CN¥390.21m

Debt

Interest coverage ratio-5.7x
CashCN¥2.73b
EquityCN¥6.12b
Total liabilitiesCN¥1.07b
Total assetsCN¥7.19b

Recent financial health updates

Recent updates

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12
Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04
Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03
Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10
Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07
Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27
Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16
Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?

Feb 23
Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?

What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?

Feb 05
What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?

Does Shanghai Haohai Biological Technology's (HKG:6826) Statutory Profit Adequately Reflect Its Underlying Profit?

Jan 21
Does Shanghai Haohai Biological Technology's (HKG:6826) Statutory Profit Adequately Reflect Its Underlying Profit?

Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Should Think About This Before Buying It For Its Dividend

Jan 06
Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Should Think About This Before Buying It For Its Dividend

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Dec 22
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

What Does Shanghai Haohai Biological Technology's (HKG:6826) CEO Pay Reveal?

Dec 07
What Does Shanghai Haohai Biological Technology's (HKG:6826) CEO Pay Reveal?

Is The Market Rewarding Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

Nov 24
Is The Market Rewarding Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

Financial Position Analysis

Short Term Liabilities: 6826's short term assets (CN¥3.7B) exceed its short term liabilities (CN¥689.8M).

Long Term Liabilities: 6826's short term assets (CN¥3.7B) exceed its long term liabilities (CN¥381.0M).


Debt to Equity History and Analysis

Debt Level: 6826 has more cash than its total debt.

Reducing Debt: 6826's debt to equity ratio has increased from 1% to 6.4% over the past 5 years.

Debt Coverage: 6826's debt is well covered by operating cash flow (161.6%).

Interest Coverage: 6826 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.